



# COVID-19 Vaccine Roll-out

## GENERAL PRACTICE EXPRESSION OF INTEREST – NOVAVAX VACCINE

The Therapeutic Goods Administration (TGA) has provisionally approved Novavax and, pending advice from the vaccination experts on the Australian Technical Advisory Group on Immunisation (ATAGI), this Expression of Interest (EOI) is for general practices and Commonwealth Vaccination Clinics who are currently participating in the COVID-19 Vaccination Program to indicate their interest to receive an ongoing allocation of the Nuvaxovid (Novavax COVID-19) vaccine. This would be in addition to Vaxzevria (AstraZeneca) vaccine, Comirnaty (Pfizer) vaccine and/or SpikeVax (Moderna) vaccine allocations.

With TGA provisional approval and pending advice from ATAGI this EOI is intended to identify existing participating general practices and Commonwealth Vaccination Clinics who are interested in also receiving an allocation of the Novavax vaccine for individuals **over 18 years old who have not received their primary course vaccinations and have expressed an interest in this vaccine.**

Interested practices will receive an initial ongoing allocation up to **200 doses per fortnight** of Novavax (to be used for first and second doses only). Practices will be able to request an increase in allocation after the first administration week. It should be noted that Novavax has not applied for regulatory authorisation to be used as a booster, so Novavax cannot be used as a booster dose at this time.

### Expression of Interest process

The Department is seeking expressions of interest from general practices. The EOI process opens from **Friday 21 January 2022** and closes at **5pm on Wednesday 26 January 2022.**

Primary Health Networks (PHNs) will coordinate this process within their regions, including for CVCs. Sites approved for the administration of Novavax through this EOI process, are expected to be able to place orders for the new product in CVAS in staged tranches starting from February 2022.

Novavax COVID-19 vaccine will also be included in the standing Expression of Interest open for all general practices interested in expanding their participation in the Program. If you would like to take time to assess the need in your area, you can be onboarded at any time. **The EOI deadline is only for those practices wanting delivery in the first delivery windows from mid to late February.**

### Important information for practices interested in administering Novavax

Prior to receiving vaccine doses sites will be required to complete the Novavax Site Readiness Declaration in the COVID-19 Vaccine Administrative System (CVAS).

Practices are reminded they **should not book appointments** until the administration of Novavax has been confirmed to be included in the program following ATAGI advice and the delivery dates for the new product have been confirmed.